Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | LCAT | P04180 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4823766 | 0.99 | CYP11B2 (0.39) | CYP11B2CYP11B1NR1H2NR1H3LCAT | |
| SCHEMBL4825581 | 0.80 | CYP11B2 (0.38) | CYP11B2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL905230 | 0.79 | NR1H2 (0.39) | CYP11B2CYP11B1NR1H2NR1H3LCAT | |
| Hydrochloric Acid SCHEMBL4822795 | 0.78 | NR1H2 (0.38) | CYP11B2CYP11B1NR1H2NR1H3LCAT | |
| SCHEMBL23515173 | 0.77 | IDH2 (0.46) | NR1H2NR1H3MAPK1 | |
| SCHEMBL5107911 | 0.77 | NR1H2 (0.39) | CYP11B2CYP11B1NR1H2NR1H3LCAT | |
| SCHEMBL21624823 | 0.77 | IDH2 (0.46) | NR1H2NR1H3MAPK1 | |
| SCHEMBL21624824 | 0.77 | IDH2 (0.46) | NR1H2NR1H3MAPK1 | |
| SCHEMBL5094697 | 0.76 | CYP11B2 (0.37) | CYP11B2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5107359 | 0.75 | NR1H2 (0.38) | CYP11B2CYP11B1NR1H2NR1H3LCAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1192028-C | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2005-03-09 | — | — | CN | claimed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | claimed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | claimed |
| EP-1178982-B1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LAB (US) | 2004-06-30 | — | — | EP | claimed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | claimed |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-05 | — | — | US | disclosed |
| US-9782404-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-10-10 | — | — | US | disclosed |
| US-9463190-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140371208-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA | 2014-12-18 | — | — | US | disclosed |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | UNIVERSITY OF SOUTH FLORIDA | 2011-09-29 | — | — | US | disclosed |
| EP-2300012-A2 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | University of South Florida (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110059905-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA | 2011-03-10 | — | — | US | disclosed |
| CN-1192028-C | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2005-03-09 | — | — | CN | disclosed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | disclosed |
| EP-1178982-B1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LAB (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | disclosed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | disclosed |
| EP-1178982-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071534-A1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LABORATORIES (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371208-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CYP11B2 1798/4885CYP11B1 1904/4885NR1H2 754/4885 |
| US-20110059905-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CYP11B2 1798/4885CYP11B1 1904/4885NR1H2 754/4885 |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CYP11B2 1798/4885CYP11B1 1904/4885NR1H2 754/4885 |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ACHE, CHRNA6, CHRNB2 | CYP11B2 4362/4885CYP11B1 4547/4885NR1H2 512/4885 |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | GRIN3A, GAP43, GRIN3B | CYP11B2 335/4885CYP11B1 387/4885NR1H2 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.